abs108.txt	background		trc105	is	an	igg1	endoglin	monoclonal	antibody	that	potentiates	vegfinhibitors	in	preclinical	models	we	assessed	safety	pharmacokinetics	andantitumor	activity	of	combination	with	axitinib	patients	withmetastatic	renal	cell	carcinoma	(mrcc)	subjects	materials	and	methods	heavily	pretreated	mrcc	were	treatedwith	weekly	(8	mg/kg	then	10	mg/kg)	axitinib(initially	at	5	mg	b	i	d	escalated	per	patient	tolerance	to	a	maximumof	)	until	disease	progression	or	unacceptable	toxicity	using	astandard	3	+	phase	design	results	eighteen	(median	number	prior	therapies	=	3)	treated	dose	escalation	proceeded	without	dose-limitingtoxicity	adverse	event	characteristics	each	drug	not	increased	infrequency	severity	when	the	two	drugs	administered	concurrently	trc105and	demonstrated	preliminary	evidence	including	partialresponses	(pr)	by	recist	29%	median	progression-free	survival(11	months)	none	pr	had	first-line	treatment	lower	baseline	levels	osteopontin	higher	tgf-Î²	receptor3	correlated	overall	response	rate	conclusion	8	was	well	tolerated	combinationwith	encouraging	amulticenter	randomized	ii	trial	has	recentlycompleted	enrollment	(nct01806064)	implications	for	practice	(cd105)	areceptor	densely	expressed	on	proliferating	endothelial	cells	also	renalcancer	stem	implicated	as	mediator	resistance	inhibitors	ofthe	vegf	pathway	this	combined	safely	atthe	recommended	single	agent	doses	cellcarcinoma	durable	vegfinhibitor-refractory	population	modulated	several	angiogenic	biomarkers	arandomized	testing	clearcell	completed	accrual
